Moderna mRNA Technology

Moderna launches mRNA bird flu vaccine trial

Moderna launches mRNA bird flu vaccine trial after HHS cancels funding

The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed help develop mRNA vaccines.

BioPharma Dive · 7h

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

· 1d

Moderna starts late-stage trial of bird flu vaccine in US, UK

· 5h

Moderna Starts Large Bird Flu Study Despite Earlier HHS Funding Loss

A new effort to prepare for future bird flu outbreaks is moving forward, despite a major funding setback.

STAT · 8h

Increased calls to 988 hotline associated with a drop in suicides among young people, study finds

· 1d

UK and US begin human bird flu vaccine trial to fight evolving virus threat

Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports encouraging response rates and a favorable safety profile for the investigational combination in early stage testing.

20h

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC

Zacks Investment Research on MSN

Moderna (MRNA) surpasses market returns: Some facts worth knowing

Moderna (MRNA) closed the most recent trading day at $55.60, moving +2.53% from the previous trading session. This change outpaced the S&P 500's 1.05% gain on the day. On the other hand, the Dow registered a gain of 0.

AOL

FDA refuses to review Moderna’s application for mRNA flu vaccine, company says

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology that’s been a target of some Trump administration health ...

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's

NBC 10 Philadelphia

Moderna says the FDA will consider its new flu shot after resolving a public dispute

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind shot. Moderna announced the change Wednesday, about a week ...